share_log

啓明醫療-B：截至二零二四年十二月三十一日止年度之年度業績公告

VENUS MEDTECH-B: ANNOUNCEMENT OF ANNUAL RESULTS FOR THE YEAR ENDED DECEMBER 31, 2024

HKEX ·  Mar 28 13:40

Summary by Moomoo AI

啟明醫療公佈截至2024年12月31日止年度業績。年內營業收入為人民幣4.71億元，同比下降4.2%；毛利為人民幣3.68億元，毛利率為78.1%。商業化利潤率由去年同期的9.3%大幅提升至20.7%，展現公司「利潤化」戰略成效。海外收入達人民幣8,250萬元，同比增長13.5%，佔總收入17.5%。公司持續聚焦結構性心臟病領域，優化研發管線佈局。自主研發的首款自膨干瓣TAVR產品Venus-PowerX、首款球擴干瓣TAVR產品Venus-Vitae和肺動脈瓣膜產品VenusP-Valve相繼開展臨床試驗。三尖瓣置換產品Cardiovalve歐洲關鍵性臨床研究患者入組進展順利，展現優秀的安全...展開全部
啟明醫療公佈截至2024年12月31日止年度業績。年內營業收入為人民幣4.71億元，同比下降4.2%；毛利為人民幣3.68億元，毛利率為78.1%。商業化利潤率由去年同期的9.3%大幅提升至20.7%，展現公司「利潤化」戰略成效。海外收入達人民幣8,250萬元，同比增長13.5%，佔總收入17.5%。公司持續聚焦結構性心臟病領域，優化研發管線佈局。自主研發的首款自膨干瓣TAVR產品Venus-PowerX、首款球擴干瓣TAVR產品Venus-Vitae和肺動脈瓣膜產品VenusP-Valve相繼開展臨床試驗。三尖瓣置換產品Cardiovalve歐洲關鍵性臨床研究患者入組進展順利，展現優秀的安全性和有效性。公司積極推進銷售模式轉型，加強銷售團隊建設。在TAVR領域保持國內市場領先地位，已累計覆蓋超過650家醫院。海外業務方面，新增商業化國家13個，已覆蓋歐洲、北美、中東、東南亞、拉美等60餘個國家，不斷完善的直銷和經銷商模式為未來產品出海打下良好商業化基礎。
Qiming Medical announced its annual performance for the year ending December 31, 2024. The revenue for the year was RMB 0.471 billion, a year-on-year decrease of 4.2%; the gross profit was RMB 0.368 billion, with a gross margin of 78.1%. The commercialization profit margin significantly increased from 9.3% in the same period last year to 20.7%, demonstrating the effectiveness of the company's "profitability" strategy. Overseas revenue reached RMB 82.5 million, a year-on-year increase of 13.5%, accounting for 17.5% of total revenue.The company continues to focus on the structural heart disease field and optimize the R&D pipeline layout. The first self-expanding dry valve TAVR product, Venus-PowerX, the first balloon-expandable dry valve TAVR product, Venus-Vitae, and the pulmonary valve product, VenusP-Valve...Show More
Qiming Medical announced its annual performance for the year ending December 31, 2024. The revenue for the year was RMB 0.471 billion, a year-on-year decrease of 4.2%; the gross profit was RMB 0.368 billion, with a gross margin of 78.1%. The commercialization profit margin significantly increased from 9.3% in the same period last year to 20.7%, demonstrating the effectiveness of the company's "profitability" strategy. Overseas revenue reached RMB 82.5 million, a year-on-year increase of 13.5%, accounting for 17.5% of total revenue.The company continues to focus on the structural heart disease field and optimize the R&D pipeline layout. The first self-expanding dry valve TAVR product, Venus-PowerX, the first balloon-expandable dry valve TAVR product, Venus-Vitae, and the pulmonary valve product, VenusP-Valve, have all commenced clinical trials. The Cardiovalve tricuspid valve replacement product's key clinical study in Europe is progressing smoothly with patient enrollment, showcasing excellent safety and efficacy.The company is actively promoting the transformation of its sales model and strengthening the construction of its sales team. It maintains a leading position in the domestic market for TAVR, covering more than 650 hospitals to date. In terms of overseas business, 13 new commercialized countries have been added, covering over 60 countries including Europe, North America, the Middle East, Southeast Asia, and Latin America. The continuously improving direct sales and Dealers model has laid a solid commercial foundation for future product exports.

This announcement is a separate document:

Doc 1     View Translation

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
Comment Comment · Views 263

Recommended

Market Insights

Market Hot Picks Market Hot Picks
No. Symbol Price
Tesla
TSLA
282.760
NVIDIA
NVDA
110.420
Newsmax
NMAX
52.520
4
CoreWeave
CRWV
61.360
5
Palantir
PLTR
87.450
Log In for the Full List
Unlock Now

Discussing

Chinese stock earnings surge: Will profit sustain the rally?
1. Which sectors are likely to be market highlights this season? 2. With the government's emphasis on technological innovation and sustaina Show More
Can strong earnings reports drive Chinese concept stocks to continue rising?
78%
22%
Bullish
Bearish
1563 votes
China's Two Sessions: Key Takeaways on Stock Price Movements Before and After the Meetings
On Tuesday, China's political leadership is convening at the Great Hall of the People in Beijing for the year's most significant event, known as the "Two Sessions." These closed-door meetings are the annual plenary sessions of both the National People's Congress and the Chinese People's Political Consultative Conference, typically held simultaneously in March. The sessions generally last for about ten days....

Discussing

FOMC holds rates amid heightened uncertainty: Where will US stocks head next?
🎙️Discussion 1. With the Fed highlighting "elevated uncertainty", are you prioritizing rate projections or near-term economic data for ma Show More
Fed rate cut expectations for 2025 intensify. What’s your market outlook?
44%
56%
Bullish
Bearlish
1579 votes
FOMC Press Conference, March 19, 2025

- No more -

Statement

This page is machine-translated. Moomoo tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation.
OK